Showing 1 - 11 of 11 Items
Showing 1 - 11 of 11 Items
Sort By: Relevance
Journal Article
|Research
Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Journal Article
|Commentary
2023-01-30 • American Journal of Respiratory and Critical Care Medicine
2023-01-30 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Commentary
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
2017-07-17 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Letter
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
2015-02-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Letter
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Research
2007-12-07 • American Journal of Respiratory and Critical Care Medicine
2007-12-07 • American Journal of Respiratory and Critical Care Medicine
RATIONALE: Two forms of the IFN-gamma release assay (IFNGRA) to detect tuberculosis infection are available, but neither has been evaluated in comparable HIV-infected and uninfected pers...
Journal Article
|Research
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
2021-01-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
Bedaquiline and delamanid offer the possibility of more effective and less toxic treatment for multidrug-resistant (MDR) tuberculosis (TB). With this treatment, however, so...
Journal Article
|Letter
2018-07-03 • American Journal of Respiratory and Critical Care Medicine
2018-07-03 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Commentary
2017-12-01 • American Journal of Respiratory and Critical Care Medicine
2017-12-01 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|Review
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
2016-11-17 • American Journal of Respiratory and Critical Care Medicine
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and r...
Journal Article
|Research
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
2020-07-24 • American Journal of Respiratory and Critical Care Medicine
BACKGROUND
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...
Bedaquiline and delamanid offer the possibility of more effective and less toxic multidrug-resistant tuberculosis (MDR-TB) treatment. With this treatment, however, some pa...